Business
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD is expected in early 2027 and as a potential disease-modifying treatment in early 2028 MALVERN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnolo
About this update from Annovis Bio, Inc.
[{"type":"image","alt":"Annovis Bio Inc.","displaySize":"","headline":null,"caption":"Annovis Bio Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V2aX3COZJf3aT17udXAGAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MA--/https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb","width":200,"height":200},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/V2aX3COZJf3aT17udXAGAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MA--/https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb","width":200,"height":200}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD is expected in early 2027 and as a potential disease-modifying treatment in early 2028","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":355,"olType":false},{"type":"text","content":"MALVERN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the first quarter ended March 31, 2026.","length":420,"tagName":"p"},{"type":"text","content":""We saw strong momentum across both our AD and PD programs in the first quarter," said Maria Maccecchini, Ph.D., President and CEO of Annovis. “Our Phase 3 AD clinical trial achieved significant enrollment growth, keeping us firmly on track to complete randomization of patients in summer 2026 and deliver first top-line results in early 2027. Simultaneously, we launched a PD OLE study and have been encouraged by the robust interest from both returning and new patients. This year is pivotal: we expe...